Trading Ideas

…read more […]

(Bloomberg) — Broadcom Inc., a major Apple Inc. supplier, suggested the latest iPhones will be launched later than usual this year.Hock Tan, chief executive officer of Broadcom, discussed a “major product cycle delay” at a “large North American mobile phone” customer, during an earnings conference call with analysts on Thursday.Tan often refers to Apple this way. This time, the executive said the delay will mean the bump in wireless revenue experienced by Broadcom will happen one quarter later than usual this year.“We are in,” Hock said, referring Broadcom components in the iPhone. “The question is timing.”“This year, we do not …read more […]

Taking the term penny stock to a whole new level, we have Seanergy Maritime (SHIP). Shares are going for $0.12 apiece following another year of massive share price depreciation. The stock is down by 78% so far in 2020. Zoom out by five years and add in bouts of shareholder dilution, and the stock is only 0.25% away from a 100% decline.However, not all hope is lost. In fact, Maxim analyst Tate Sullivan remains firmly in the shipping company’s corner.Sullivan has a Buy rating on Seanergy based on his “outlook for SHIP to use recent equity proceeds to reduce and/or …read more […]

Gilead Sciences (GILD) isn’t a one-trick pony. While the news coverage has largely fixated on its potential COVID-19 treatment, remdesivir, the large-cap has an increasingly diverse pipeline.In addition to the headline grabbing remdesivir, Gilead is the biggest player in the HIV space, manufacturing what could become the best-selling HIV drug ever, Biktarvy.Having said that, Gilead has been expanding, and through a series of M&As, building an increasingly strong oncology portfolio. Following the addition of Kite in 2018 and the more recent acquisition of cancer-focused biotech Forty Seven, Gilead has just inked a deal with immuno-oncology player Arcus Biosciences. They have …read more […]

There’s no doubt about it, Moderna’s (MRNA) profile has increased dramatically since the pandemic’s onset.The biotech name has climbed 206% higher this year, as investors have piled in with the hope that its COVID-19 vaccine candidate, mRNA-1273, might be the one to solve the coronavirus conundrum. Yet, it hasn’t all been positive news. Recently, questions have surfaced concerning the company’s sale of shares following the stock’s latest surge.Blocking out all of the noise, Oppenheimer analyst Hartag Singh recently attended Moderna’s virtual Science Day to get some visibility on the work going on behind the scenes. The 5-star analyst liked what …read more […]

…read more […]

Rewind to the end of 2019, and in the dead of winter, the sun appeared to be shining on biotech Amarin (AMRN). Vascepa, the company’s high triglycerides treatment and only product, had just received label expansion approval from the FDA, and a large commercial opportunity beckoned.But the rug was pulled out from underneath Amarin’s feet in one swift move. In March, the company lost a patent trial against two generic drug makers, Dr. Reddy’s and Hikma Pharmaceuticals, seeking to sell their own versions of Vascepa. Accordingly, a massive sell off ensued. Amarin has since filed its appeal, and the generic …read more […]

Editor’s Note: Today, Contributing Analyst Jody Chudley shares some of the simplest investing advice he’s ever received, but corporate America has still failed to take it to heart.
The truth is, many of the market’s top executives get distracted chasing the wrong metrics for success.
That’s why Chief Income Strategist Marc Lichtenfeld wants investors to avoid making the same mistake.
Instead of following the faulty metric Jody describes below, take a look at Marc’s March interview in U.S. News & World Report to discover which signals will best guide your portfolio.
>Click here to read the full interview. …read more […]

…read more […]

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of March 31st, 2020. […] …read more […]

You could have made 50% in one day with Party City (NYSE: PRTY) shares a week ago. It was a trend reversal following a massive downturn for the stock.
This obvious pariah of social distancing has seen its shares tank from $8 to $0.26 over the past year.
After all, who’s going to be throwing parties when the end result is possible death from the coronavirus?
Well, conventional wisdom is often wrong…
Just look at the move in casino stocks, airline stocks, hotel stocks and even theme park stocks since the lows in March. Some have doubled and even tripled.
Casinos reopened with bigger-than-expected crowds. …read more […]

…read more […]

The cannabis sector generally took a step back after Canopy Growth (CGC) reported a disastrous quarter last week. The Canadian cannabis giant set the sector back after cannabis was generally seen in a positive light coming out of the economic shutdown due to the coronavirus. While the U.S. cannabis space is poised for a strong 2H of the year, the sector wasn’t completely unscathed during the coronavirus shutdown. A few states such as Massachusetts and Nevada closed stores during the virus outbreak hitting revenues hard in those states.While some of the large multi-state operators (MSOs) have rallied near pre-virus …read more […]

(Bloomberg) — U.S. airlines and rental car stocks added $8.6 billion in market value Thursday after American Airlines Group Inc. said it plans to boost flights by 74% next month, suggesting that the worst of the pandemic-led travel standstill has passed.American surged 41% — adding $2.1 billion to its own market value — after saying its July schedule would see about 4,000 flights on its busiest days, up from about 2,300 flights now. Rival airlines, as well as rental car operators Hertz Global and Avis Budget Group, also rose as the expanded schedule echoed indications from peers that passenger demand …read more […]

As the S&P 500 (^GSPC) hovers around 40% from its March 23rd low, one veteran strategist is reminded of the massive rally that took place when the markets were emerging from the financial crisis 11 years ago. …read more […]